Gene Therapy Reaches XLRS Milestone - Scorecard - MDSpire

Gene Therapy Reaches XLRS Milestone

Atsena Therapeutics reports positive interim data for XLRS gene therapy

  • May 25, 2026

  • 3 min

Share

Clinical Scorecard: Gene Therapy Reaches XLRS Milestone

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPrimarily affects males, diagnosed in childhood.
Care Setting

Key Highlights

  • Structural and functional improvements observed in treated adults.
  • Foveal schisis closure confirmed in treated adults.
  • Enrollment underway for Part C of the trial.

Guideline-Based Recommendations

Diagnosis

    Management

    • ATSN-201 is being evaluated as a gene therapy treatment option.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Safety findings in pediatric patients consistent with adults.

        Clinical Best Practices

        • Monitor for foveal schisis closure in treated patients.
        • Utilize microperimetry and OCT for assessing treatment outcomes.

        Related Resources & Content

        Original Source(s)

        Gene Therapy Reaches XLRS Milestone

        • May 25, 2026

        Related Content

        FDA Clears Nocturnal IOP Device

        Balance Ophthalmics gains FDA 510(k) clearance for wireless FSYX glaucoma device

        • May 26, 2026

        • 2 min
        Refocusing Retinal Imaging

        New study looks at extending retinal focus using computational adaptive optics framework

        • May 26, 2026

        • 4 min
        "All Eyes on DME"

        Genentech launches diabetic macular edema awareness campaign fronted by actor and comedian, Damon Wayans

        • May 22, 2026

        • 3 min